The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

Diabetologia

Volumn 60, Issue 2, 2017, Pages 364-376

  Han, Ji Hye ^a   Oh, Tae Jung ^a   Lee, Ghayoung ^a   Maeng, Hyo Jin ^a   Lee, Dong Hwa ^a   Kim, Kyoung Min ^a   Choi, Sung Hee ^a   Jang, Hak Chul ^a   Lee, Hye Seung ^a   Park, Kyong Soo ^a   Kim, Young Bum ^b   Lim, Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Insulin resistance; Sodium glucose cotransporter; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALBUMIN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; BENZHYDRYL DERIVATIVE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; GLUCOSIDE; GLYCOPROTEIN P 15095; LEUKOCYTE ANTIGEN; SODIUM GLUCOSE COTRANSPORTER 2;

ADIPOSE TISSUE; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ATHEROSCLEROSIS; AORTIC SMOOTH MUSCLE CELL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY COMPOSITION; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIMIT OF QUANTITATION; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; URINARY TRACT INFECTION; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; PHYSIOLOGY; RAT; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZHYDRYL COMPOUNDS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DIET, WESTERN; GLUCOSIDES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MICE; RATS; REAL-TIME POLYMERASE CHAIN REACTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84995768100     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4158-2     Document Type: Article

References (51)

1. Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397–404
2. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31–38
3. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L (1991) Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561–570
4. Chasis H, Jolliffe N, Smith HW (1933) The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 12:1083–1090
5. Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255–270
6. Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11:79–88
7. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ (2013) A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15:721–728
8. Goring S, Hawkins N, Wygant G et al (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16:433–442
9. Stenlof K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372–382
10. Liakos A, Karagiannis T, Athanasiadou E et al (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16:984–993
11. Bolinder J, Ljunggren O, Kullberg J et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020–1031
12. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650–657
13. Perkins BA, Cherney DZ, Partridge H et al (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480–1483
14. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
15. Terasaki M, Hiromura M, Mori Y et al (2015) Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One 10, e0143396
16. Nakajima K, Mita T, Osonoi Y et al (2015) Effect of repetitive glucose spike and hypoglycaemia on atherosclerosis and death rate in Apo E-deficient mice. Int J Endocrinol 2015:406394
17. Wu KK, Huan Y (2007) Diabetic atherosclerosis mouse models. Atherosclerosis 191:241–249
18. Lim S, Lee KS, Lee JE et al (2015) Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 243:107–119
19. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
20. Stringer DM, Zahradka P, Declercq VC et al (2010) Modulation of lipid droplet size and lipid droplet proteins by trans-10, cis-12 conjugated linoleic acid parallels improvements in hepatic steatosis in obese, insulin-resistant rats. Biochim Biophys Acta 1801:1375–1385
21. Lim S, Moon MK, Shin H et al (2011) Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats. Cardiovasc Res 90:383–393
22. Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159:262–274
23. Chen L, Klein T, Leung PS (2012) Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 12:995–1004
24. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M (2009) Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85:513–519
25. Yamamoto K, Uchida S, Kitano K et al (2011) TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164:181–191
26. Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499–508
27. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2:691–700
28. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953–964
29. Apovian CM, Bigornia S, Mott M et al (2008) Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28:1654–1659
30. Farb MG, Bigornia S, Mott M et al (2011) Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol 58:232–237
31. Carr RM, Ahima RS (2016) Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res 340:187–192
32. Hesse D, Radloff K, Jaschke A et al (2014) Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. J Lipid Res 55:41–52
33. Cho NH, Jang HC, Choi SH et al (2007) Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care 30:2566–2568
34. Lim S, Oh TJ, Koh KK (2015) Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 201:408–414
35. Freitas Lima LC, Braga VA, do Socorro de Franca Silva M et al (2015) Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol 6:304
36. Bian F, Yang X, Zhou F et al (2014) C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol 171:2671–2684
37. Uchida Y, Takeshita K, Yamamoto K et al (2012) Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1. Diabetes 61:1552–1561
38. Lin J, Kakkar V, Lu X (2014) Impact of MCP-1 in atherosclerosis. Curr Pharm Des 20:4580–4588
39. Funahashi T, Nakamura T, Shimomura I et al (1999) Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202–206
40. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 52:1779–1785
41. Liu Q, Anderson C, Broyde A et al (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76
42. Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD (2014) Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord 15:209–217
43. Lim S, Quon MJ, Koh KK (2014) Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 233:721–728
44. Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Maciel PM, Reaven GM (2014) Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio. Am J Med 127:152–157
45. Wang D, Liu B, Tao W, Hao Z, Liu M (2015) Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 10, CD009580
46. Briand F, Mayoux E, Brousseau E et al (2016) Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes 65:2032–2038
47. Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572–2581
48. Papathanassiou K, Naka KK, Kazakos N et al (2009) Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 205:221–226
49. Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S (2015) Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64:2028–2041
50. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223–2233
51. Lim S, Choi SH, Shin H et al (2012) Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 7, e35007